Philadelphia-negative myeloproliferative neoplasms among Kuwaiti Nationals

被引:1
作者
Alshemmari, Salem [1 ]
Almazyad, Mazyad [2 ]
Alwehaib, Aisha [2 ]
Ameen, Reem [3 ]
机构
[1] Fac Med, Dept Med, Safat, Kuwait
[2] Kuwait Univ, Fac Med, Safat, Kuwait
[3] Fac Allied Hlth, Dept Med Lab Sci, Safat, Kuwait
关键词
driver mutations; epidemiology; Myeloproliferative neoplasms; WORLD-HEALTH-ORGANIZATION; TYROSINE KINASE JAK2; MYELOID NEOPLASMS; 2016; REVISION; MUTATION; CLASSIFICATION; EPIDEMIOLOGY; PREVALENCE; DISORDERS; SURVIVAL;
D O I
10.1002/cam4.3633
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The epidemiology, genetics, and thrombosis risk of MPNs among Arabs are largely unknown. This may be attributed to scarce epidemiological data, particularly from our region. Our study included 381 Kuwaiti nationals with Ph-negative MPNs and a confirmed driver mutation involving JAK2 (exon 12 14), CALR, or MPL. This first regional study examines the demographics, clinical parameters, and thrombosis-related attributes of the participants. This study reported a median age of 58 years, with females and males representing 54.9% and 45.1%, respectively. ET was the most frequent subtype of Ph-negative MPNs in our population, accounting for 52.0% of the cases, followed by PV, found in 34.6% of the participants, and PMF, found in 8.4% of participants. The crude annual cumulative incidence of Ph-negative MPNs in Kuwait ranged from 0.674 to 3.177 per 100,000 population across the study period. The most common driver mutation was JAK2V617F, with a frequency of 89.5%. At diagnosis, 19.2% of the patients presented with unexplained thrombosis, and almost half were of arterial origins. Males were more likely to present with arterial thrombosis than females (61.5% vs. 35.3%), whereas venous thrombotic events were more common in females than in males (47.1% vs. 17.9%; p-value = 0.025). Ph-negative MPNs in Kuwait are rare; however, thrombosis is a frequent complication, being documented in up to 19.2% of cases at presentation, more commonly at arterial sites. These findings call for thorough evaluation of patients with unexplained derangements in their hematological parameters during follow-ups.
引用
收藏
页码:365 / 371
页数:7
相关论文
共 23 条
[1]   Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms [J].
Arachchillage, Deepa R. J. ;
Laffan, Mike .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2019, 45 (06) :604-611
[2]   The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J].
Arber, Daniel A. ;
Orazi, Attilio ;
Hasserjian, Robert ;
Thiele, Jurgen ;
Borowitz, Michael J. ;
Le Beau, Michelle M. ;
Bloomfield, Clara D. ;
Cazzola, Mario ;
Vardiman, James W. .
BLOOD, 2016, 127 (20) :2391-2405
[3]   Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].
Baxter, EJ ;
Scott, LM ;
Campbell, PJ ;
East, C ;
Fourouclas, N ;
Swanton, S ;
Vassiliou, GS ;
Bench, AJ ;
Boyd, EM ;
Curtin, N ;
Scott, MA ;
Erber, WN ;
Green, AR .
LANCET, 2005, 365 (9464) :1054-1061
[4]   A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [J].
James, C ;
Ugo, V ;
Le Couédic, JP ;
Staerk, J ;
Delhommeau, F ;
Lacout, C ;
Garçon, L ;
Raslova, H ;
Berger, R ;
Bennaceur-Griscelli, A ;
Villeval, JL ;
Constantinescu, SN ;
Casadevall, N ;
Vainchenker, W .
NATURE, 2005, 434 (7037) :1144-1148
[5]   Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms [J].
Klampfl, Thorsten ;
Gisslinger, Heinz ;
Harutyunyan, Ashot S. ;
Nivarthi, Harini ;
Rumi, Elisa ;
Milosevic, Jelena D. ;
Them, Nicole C. C. ;
Berg, Tiina ;
Gisslinger, Bettina ;
Pietra, Daniela ;
Chen, Doris ;
Vladimer, Gregory I. ;
Bagienski, Klaudia ;
Milanesi, Chiara ;
Casetti, Ilaria Carola ;
Sant'Antonio, Emanuela ;
Ferretti, Virginia ;
Elena, Chiara ;
Schischlik, Fiorella ;
Cleary, Ciara ;
Six, Melanie ;
Schalling, Martin ;
Schoenegger, Andreas ;
Bock, Christoph ;
Malcovati, Luca ;
Pascutto, Cristiana ;
Superti-Furga, Giulio ;
Cazzola, Mario ;
Kralovics, Robert .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (25) :2379-2390
[6]   A gain-of-function mutation of JAK2 in myeloproliferative disorders [J].
Kralovics, R ;
Passamonti, F ;
Buser, AS ;
Teo, S ;
Tiedt, R ;
Passweg, JR ;
Tichelli, A ;
Cazzola, M ;
Skoda, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) :1779-1790
[7]   Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis [J].
Levine, RL ;
Wadleigh, M ;
Cools, J ;
Ebert, BL ;
Wernig, G ;
Huntly, BJP ;
Boggon, TJ ;
Wlodarska, L ;
Clark, JJ ;
Moore, S ;
Adelsperger, J ;
Koo, S ;
Lee, JC ;
Gabriel, S ;
Mercher, T ;
D'Andrea, A ;
Fröhling, S ;
Döhner, K ;
Marynen, P ;
Vandenberghe, P ;
Mesa, RA ;
Tefferi, A ;
Griffin, JD ;
Eck, MJ ;
Sellers, WR ;
Meyerson, M ;
Golub, TR ;
Lee, SJ ;
Gilliland, DG .
CANCER CELL, 2005, 7 (04) :387-397
[8]   Epidemiology of myeloproliferative neoplasms in the United States [J].
Mehta, Jyotsna ;
Wang, Hongwei ;
Iqbal, Sheikh Usman ;
Mesa, Ruben .
LEUKEMIA & LYMPHOMA, 2014, 55 (03) :595-600
[9]   Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2 [J].
Nangalia, J. ;
Massie, C. E. ;
Baxter, E. J. ;
Nice, F. L. ;
Gundem, G. ;
Wedge, D. C. ;
Avezov, E. ;
Li, J. ;
Kollmann, K. ;
Kent, D. G. ;
Aziz, A. ;
Godfrey, A. L. ;
Hinton, J. ;
Martincorena, I. ;
Van Loo, P. ;
Jones, A. V. ;
Guglielmelli, P. ;
Tarpey, P. ;
Harding, H. P. ;
Fitzpatrick, J. D. ;
Goudie, C. T. ;
Ortmann, C. A. ;
Loughran, S. J. ;
Raine, K. ;
Jones, D. R. ;
Butler, A. P. ;
Teague, J. W. ;
O'Meara, S. ;
McLaren, S. ;
Bianchi, M. ;
Silber, Y. ;
Dimitropoulou, D. ;
Bloxham, D. ;
Mudie, L. ;
Maddison, M. ;
Robinson, B. ;
Keohane, C. ;
Maclean, C. ;
Hill, K. ;
Orchard, K. ;
Tauro, S. ;
Du, M-Q ;
Greaves, M. ;
Bowen, D. ;
Huntly, B. J. P. ;
Harrison, C. N. ;
Cross, N. C. P. ;
Ron, D. ;
Vannucchi, A. M. ;
Papaemmanuil, E. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (25) :2391-2405
[10]  
NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85